Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Affiliations

• ¹ Department of Internal Medicine I, Klinikum Schwabing, Munich, Germany.
• ² Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany.
• ³ Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
• ⁴ Department of Internal Medicine III, Ulm University, Ulm, Germany.
• ⁵ Internal Medicine, Hematology and Oncology Private Practice, Erlangen, Germany.
• ⁶ Oncological Private Practice, Landshut, Germany.
• ⁷ Internal Medicine, Hematology and Oncology Private Practice, Saarbrücken, Germany.
• ⁸ Department of Internal Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
• ⁹ Internal Medicine, Hematology and Oncology Private Practice, Halle, Germany.
• ¹⁰ Department of Internal Medicine I, Division of Bone Marrow Transplantation, Medical University of Vienna, Vienna, Austria.
• ¹¹ Department of Hematology and Oncology, Klinikum Lippe-Lemgo, Lemgo, Germany.
• ¹² Department of Hematology, Oncology and Palliative Medicine, Klinikum Bad Saarow, Bad Saarow, Germany.
• ¹³ Hematology and Oncology Private Practice, Munich, Germany.
• ¹⁴ Hematology and Oncology Private Practice, Berlin, Germany.
• ¹⁵ Hematology and Oncology Private Practice, Hildesheim, Germany.
• ¹⁶ Hematology and Oncology Private Practice, Leer, Germany.
• ¹⁷ Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
• ¹⁸ Department of Internal Medicine III, Klinikum Karlsruhe, Karlsruhe, Germany.
• ¹⁹ Interdisciplinary Oncology Center (IOZ) Private Practice, Munich, Germany.